Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial
Authors' conclusion
In this short-term controlled study of adults with T1DM, adjunctive dapagliflozin was associated with improved CGM-derived glycemic control and reduced insulin dose versus acarbose, without diabetic ketoacidosis events. Longer term studies are warranted.
Study context
- Population
- Adults with T1D aged 18–60 years, HbA1c ≤ 9.0%44 completed both periods
- Comparison
- Dapagliflozin vs acarbose as adjuncts to insulin
- Primary endpoint
- TIR (3.9-10.0 mmol/L) on blinded continuous glucose monitoring (CGM)
- Follow-up
- Final 14 days of each 4-week period
Methodological detailsprospective, open-label, 2-week washout
- Prospective
- Open-label
- 2-week washout
Primary result
As reported in the abstract
P < 0.001
Further findings
Total daily insulin dose · during treatment · lower with dapagliflozin
P = 0.001
Time in range (TIR) change from baseline with dapagliflozin · baseline to end of treatment
- TIR with dapagliflozin, baseline to treatment
- 55.4% to 68.2%; P < .001
Mean glucose and glycemic variability (SD of blood glucose, largest amplitude of glycemic excursions) with dapagliflozin
- Reduced from baseline with dapagliflozin
- P < 0.01
Postprandial glucose excursions with acarbose
- Reduced with acarbose
- P = 0.001
Insulin requirement change from baseline with dapagliflozin
- Insulin dose with dapagliflozin vs baseline
- 31.94 U vs 38.45 U, P = .009
- Only dapagliflozin significantly reduced insulin requirements from baseline
Safety
| Outcome | P value |
|---|---|
| Hypoglycemia frequencyDid not differ | P = 0.467 |
DKA
- DKA events
- 0
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →